COMP360 psilocybin for PTSD: see if it helps reduce symptoms with guided support

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores whether COMP360, a laboratory-made psilocybin, can lessen PTSD symptoms when given alongside structured monitoring and care. It includes adults with a PTSD diagnosis for at least six months and excludes certain psychiatric conditions. The trial combines two phases (Phase 2 and Phase 3) to evaluate safety, tolerability, and efficacy. Participants receive the medication under controlled conditions with clinical support to manage effects. Primary sites are in Tucson, AZ and two California locations (Irvine and Los Angeles).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years or older
* Diagnosed with PTSD at least 6 months ago

Exclusion Criteria:

\- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions

Where it's running

• Az
  Tucson, Arizona, United States Recruiting
• Ca
  Irvine, California, United States Recruiting
• Ca
  Los Angeles, California, United States Recruiting
• Ca
  Moorpark, California, United States Recruiting
• Fl
  Miami, Florida, United States Recruiting
• Fl
  Orlando, Florida, United States Recruiting

Study contacts

• Study coordinator: www.redefineptsdstudy.com Redefine Study Call Center
• Email: TheRedefineStudy@compasspathways.com
• Phone: 202-459-9258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-invasive vagus nerve stimulation (gammaCore) for PTSD

  This study will test whether the handheld gammaCore device, which delivers mild electrical stimulation to the vagus nerve through the neck, can help adults with PTSD reduce their symptoms.

  Recruiting Acacia Clinics · Sunnyvale, California · NCT07523685

• Psilocybin treatment for individuals with various psychiatric symptoms

  This study is testing if a single dose of psilocybin can help people with different mental health issues like depression, anxiety, and PTSD feel better and improve their daily functioning.

  Recruiting Phase 1 Yale University · New Haven, Connecticut · NCT06442423

• Virtual Reality–Assisted Trauma-Focused CBT for PTSD

  A VR-assisted trauma-focused CBT approach is being tested to see if it helps adults with PTSD related to Northern Ireland–specific trauma.

  Recruiting Queen's University, Belfast · Newtownabbey, County Antrim · NCT07914634

• ReVIVE for mTBI: Using VR and therapy to help adults with mild traumatic brain injury

  This study tests a virtual reality therapy combined with standard psychotherapy to see if it can reduce PTSD symptoms and improve executive function in adults with mild traumatic brain injury.

  Recruiting Phase 1 Johns Hopkins University · Baltimore, Maryland · NCT07890337

• HBOT to see if it helps cognition and well‑being in first responders with prior brain injury

  This study tests whether 40 hyperbaric oxygen therapy sessions can improve thinking skills and post-concussion symptoms in current or former first responders with a history of brain injury.

  Recruiting Phase 2 Summit Hyperbarics and Wellness · Boise, Idaho · NCT07852728

• Predicting nightmare awakenings in PTSD using an AI algorithm

  The study tests an AI tool called CAUD-PIN to see if it can reliably predict when trauma-related nightmares will wake military personnel or veterans with PTSD.

  Recruiting at 2 sites Direction Centrale du Service de Santé des Armées · Brest and 2 other locations · NCT07851480

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.